Phase 2 N=12 A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03 — 16; 18; 13; 11 Number of Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2) — 53; 50 mmHg — p=0.01
Phase 2 N=5 An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001
Sickle Cell Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events During Dosing of GBT440 for up to 6 Months. — 2; 1; 1 Participants
N/A N=242 CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients
Non-left Bundle Branch Block · Ischemic or Non-ischemic Cardiomyopathy
Primary: Number of Patients With Improved Clinical Composite Score — 86; 45 Participants — p=0.001
Phase 4 N=50 Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery
Caloric Restriction · Exercise
Primary: Body Composition at the End of Each Study Phase — 78.3; 78.0; 73.3; 75.8 kilograms
Phase 2 N=35 IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.
Foreign-Body Reaction · Inflammation · Effusion (L) Knee
Primary: Safety: Adverse Events — 0 participants
N/A N=69 Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Lung Cancer
Primary: To Determine the Proportion of Patients Who Can be Localized by the Calypso System Using the Anchored Transponders. — 66 Participants
Phase 3 N=8 Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 7 Participants
Phase 3 N=244 A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
Parkinson's Disease
Primary: Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III Total Score — 1.87; -4.52 Units on a scale…
Phase 4 N=20 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy
Actinic Keratosis
Primary: Mean Severity Score — -1.52; -1.80 units on a scale
N/A N=321 SMS Mobile Technology for Vaccine Coverage and Acceptance
Adherence to Vaccination Schedules
Primary: Completion of 3 Doses of Pentavalent Vaccine — 135; 130 participants
Phase 3 N=1,055 A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Adverse Events: Frequency and Severity — 272; 242; 275; 226 Participants
Phase 3 N=74 Low-dose Propofol for Pediatric Migraine
Migraine Headache
Primary: Change in Self-Assessed Pain — 51; 59 percentage change
Phase 3 N=93 Ropivacaine Versus Bupivacaine as Preemptive Analgesia in Surgical Site in Ankle Fracture Patients
Ankle Fractures · Pain, Postoperative · Local Infiltration
Primary: VAS — 2.81; 2.13; 3.52; 4.52 units on a scale (VAS)
Phase 3 N=207 Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Chronic Obstructive Pulmonary Disease, COPD · Low Peak Inspiratory Flow Rate (PIFR)
Primary: Change From Baseline in Trough FEV1 on Day 29 — 63.0; 47.3 mL